Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Gynaecol Obstet. 2008 Aug;102(2):128-31. doi: 10.1016/j.ijgo.2008.04.008. Epub 2008 Jun 16.

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

Author information

1
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut 06520-8063, USA. alessandro.santin@yale.edu

Abstract

OBJECTIVE:

To study the effect of trastuzumab in patients with progressive or recurrent metastatic endometrial carcinoma shown by immunohistochemistry to overexpress the HER2/neu receptor.

METHODS:

Disease progression was examined in 2 patients who met the study criteria, had c-erbB2 gene amplification by fluorescence in situ hybridization, and were treated with trastuzumab following radiation treatment and/or salvage chemotherapy.

RESULTS:

The clinical responses to trastuzumab as a single agent or in combination with chemotherapy were confirmed in both patients by serial CT scans and serum CA-125 evaluations. These patients with progressive or recurrent metastatic disease experienced relief from their symptoms and prolonged survival with no significant toxicity observed.

CONCLUSION:

Trastuzumab may be a viable therapeutic option as single agent or in combination with chemotherapy in patients with advanced, recurrent, and/or metastatic endometrial carcinomas overexpressing HER2/neu.

PMID:
18555254
DOI:
10.1016/j.ijgo.2008.04.008
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center